Saroglitazar

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Bile acid sequestrants

1 evidence topic · 1 source

Pruritus: first-line pharmacologic treatment

“cholestyramine as first-line treatment” (opens the source at this quote in a new tab)